Moderna, Inc. MRNA will launch its fourth-quarter monetary outcomes, earlier than the opening bell, on Friday, Feb. 14, 2025.
Analysts count on the Cambridge, Massachusetts-based firm to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share within the year-ago interval. Moderna tasks quarterly income of $942.84 million, in comparison with $2.81 billion a 12 months earlier, based on knowledge from Benzinga Professional.
The corporate has topped consensus estimates on the highest and backside traces for the final 4 consecutive quarters.
Moderna shares gained 4.5% to shut at $31.92 on Thursday.
Benzinga readers can entry the newest analyst rankings on the Analyst Inventory Scores web page. Readers can type by inventory ticker, firm identify, analyst agency, score change or different variables.
Let’s take a look at how Benzinga’s most-accurate analysts have rated the corporate within the current interval.
- B of A Securities analyst Tim Anderson maintained an Underperform score and reduce the worth goal from $41 to $34 on Feb. 11, 2025. This analyst has an accuracy price of 62%.
- Evercore ISI Group analyst Cory Kaimov maintained an In-Line score and reduce the worth goal from $60 to $50 on Jan. 27, 2025. This analyst has an accuracy price of 69%.
- Argus Analysis analyst John Eade downgraded the inventory from Purchase to Maintain on Dec. 18, 2024. This analyst has an accuracy price of 74%.
- JP Morgan analyst Jessica Fye maintained an Underweight score and reduce the worth goal from $59 to $45 on Nov. 26, 2024. This analyst has an accuracy price of 62%.
Contemplating shopping for MRNA inventory? Right here’s what analysts assume:
Learn This Subsequent:
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
